These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32918927)

  • 21. Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats.
    Feng Y; Liu W; Pan L; Jiang C; Zhang C; Lu Y; Nie Z; Jin L
    Drug Des Devel Ther; 2017; 11():1927-1939. PubMed ID: 28721012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm.
    Lorenzano C; Bagnato S; Gilio F; Fabbrini G; Berardelli A
    Neurotox Res; 2006 Apr; 9(2-3):141-4. PubMed ID: 16785111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison study of prabotulinumtoxinA vs onabotulinumtoxinA in myostatin-deficient mice with muscle hypertrophy.
    Bak DH; Choi MJ; Lee E; Kwon TR; Kim JH; Nam SH; Kim KY; Ahn SW; Mun SK; Na J; Kim BJ
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):491-499. PubMed ID: 30326173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
    Matarasso A; Shafer D
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S72-9. PubMed ID: 19945008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How effective is physical therapy for gait muscle activity in hemiparetic patients who receive botulinum toxin injections?
    Fujita K; Miaki H; Hori H; Kobayashi Y; Nakagawa T
    Eur J Phys Rehabil Med; 2019 Feb; 55(1):8-18. PubMed ID: 29898587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative evaluation for spasticity of calf muscle after botulinum toxin injection in patients with cerebral palsy: a pilot study.
    Lin YC; Lin IL; Chou TF; Lee HM
    J Neuroeng Rehabil; 2016 Mar; 13():25. PubMed ID: 26969526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
    Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of botulinum toxin: differences between type A preparations.
    Rosales RL; Bigalke H; Dressler D
    Eur J Neurol; 2006 Feb; 13 Suppl 1():2-10. PubMed ID: 16417591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Precision Use of Botulinum Toxin Type A (BONT-A) in Aesthetics Based on Muscle Atrophy, Is Muscular Architecture Reprogramming a Possibility? A Systematic Review of Literature on Muscle Atrophy after BoNT-A Injections.
    Nassif AD; Boggio RF; Espicalsky S; Faria GEL
    Toxins (Basel); 2022 Jan; 14(2):. PubMed ID: 35202109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from Gastrocnemius Muscle.
    Caron G; Marqueste T; Decherchi P
    PLoS One; 2015; 10(10):e0140439. PubMed ID: 26485650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of botulinum toxin type A following long-term use.
    Naumann M; Albanese A; Heinen F; Molenaers G; Relja M
    Eur J Neurol; 2006 Dec; 13 Suppl 4():35-40. PubMed ID: 17112348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targets for botulinum toxin in the lower urinary tract.
    Cruz F
    Neurourol Urodyn; 2014 Jan; 33(1):31-8. PubMed ID: 23775898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intramuscular pressure before and after botulinum toxin in chronic exertional compartment syndrome of the leg: a preliminary study.
    Isner-Horobeti ME; Dufour SP; Blaes C; Lecocq J
    Am J Sports Med; 2013 Nov; 41(11):2558-66. PubMed ID: 23969633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm.
    Conte A; Fabbrini G; Belvisi D; Marsili L; Di Stasio F; Berardelli A
    Eur J Neurol; 2010 Mar; 17(3):449-55. PubMed ID: 19968711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of palmar hyperhidrosis with botulinum toxin type A: results of a pilot study based on a novel injective approach.
    Campanati A; Giuliodori K; Giuliano A; Martina E; Ganzetti G; Marconi B; Chiarici A; Offidani A
    Arch Dermatol Res; 2013 Oct; 305(8):691-7. PubMed ID: 23800969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study.
    Alimohammadi M; Andersson M; Punga AR
    Acta Derm Venereol; 2014 Jan; 94(1):32-7. PubMed ID: 23975053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps.
    Adler M; Capacio B; Deshpande SS
    Toxicon; 2000 Oct; 38(10):1381-8. PubMed ID: 10758273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Muscle volume alterations after first botulinum neurotoxin A treatment in children with cerebral palsy: a 6-month prospective cohort study.
    Alexander C; Elliott C; Valentine J; Stannage K; Bear N; Donnelly CJ; Shipman P; Reid S
    Dev Med Child Neurol; 2018 Nov; 60(11):1165-1171. PubMed ID: 30151852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.
    Naumann M; Dressler D; Hallett M; Jankovic J; Schiavo G; Segal KR; Truong D
    Toxicon; 2013 Jun; 67():141-52. PubMed ID: 23178324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.